Home / Compare / Thymosin Alpha-1 vs BPC-157

Thymosin Alpha-1 vs BPC-157

Thymosin Alpha-1 vs BPC-157: immune-system support vs systemic tissue repair. Here's a neutral, sourced side-by-side — no hype, every claim links to its evidence.

By The Health Stacks Research Team

Thymosin Alpha-1

Research

Also: Thymalfasin, Thymosin

Compounding pharmacies create customized peptide medications (like BPC-157, Thymosin Alpha-1, Semaglutide, and Tirzepatide) in specific dosages when commercial options are unavailable. Under Section 503A, traditional pharmacies prepare patient-specific prescriptions, while 503B outsourcing facilities can produce larger batches for healthcare facilities.

350 studies326 benefits documented
Where to Source Thymosin Alpha-1

BPC-157

Research

Also: Body Protection Compound, PL 14736

BPC-157 is a small chain of amino acids, which are the building blocks of proteins in the body. It is found naturally in the human stomach, specifically in the juices that help digest food.

197 studies602 benefits documented
Where to Source BPC-157

At a Glance

Thymosin Alpha-1BPC-157
Research statusPreclinicalPreclinical
Benefits documented326602
Research citations350197
Dosing routesSubcutaneousSubcutaneous
Known side effects5060

What Each Helps With

Top documented benefits — backed by research.

Thymosin Alpha-1

  • Immune modulation (T-cell)
  • Adjunct for chronic hepatitis B

BPC-157

  • Tendon/ligament repair
  • Angiogenesis
  • Anti-inflammatory

How People Use It

Reported protocols — research only, not medical advice.

Thymosin Alpha-1

  • subcutaneous — 1.6 mg (900 mcg/m2)
  • subcutaneous — 5 mg/kg
  • subcutaneous — Topical ophthalmic solution, 4-6x daily
  • subcutaneous — Injection (specific dose not provided)

BPC-157

  • subcutaneous — Once daily (varies by study)
  • subcutaneous — Oral/IM use is permitted; WADA only prohibits IV infusion >100 mL / 12 hr
  • subcutaneous — Intrathecal only
  • subcutaneous — First-in-human Phase 1 study dose (unspecified quantity)

The Evidence

Key studies — click through to verify each on PubMed.

Thymosin Alpha-1

350 sourced studies

  • Thymosin alpha 1: A comprehensive review of the literature

    Review2020 Key study 84/100
    Source

  • FDA orphan drug designation - Thymosin Alpha-1 (Ta1)

    Guideline2023 85/100
    Source

  • Thymosin alpha 1: A comprehensive review of the literature

    2020 90/100
    Source

  • Thymosin alpha1: a historical overview

    2007 90/100
    Source

BPC-157

197 sourced studies

  • The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.

    In vitro2010 Key study 85/100
    Source

  • Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

    Review2019 80/100
    Source

  • Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

    In vitro2018 84/100
    Source

  • Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing

    Review2025 76/100
    Source

How to Choose

Neither is a “winner” — they suit different goals. Compare the documented benefits and evidence above against what you’re actually trying to achieve, note the research status (approved vs research-stage), and read each full guide before deciding. Many people also stack peptides rather than pick one.

Full Thymosin Alpha-1 guide →Full BPC-157 guide →See stacks →

Source Thymosin Alpha-1

Find Thymosin Alpha-1 Suppliers
Tested purity COA available Fast shipping

Source BPC-157

Find BPC-157 Suppliers
Tested purity COA available Fast shipping
Educational content only. Peptides discussed are generally research compounds, not FDA-approved for human use unless stated. Consult a healthcare professional before use.